Next Article in Journal
Summary-Based Methylome-Wide Association Analyses Suggest Potential Genetically Driven Epigenetic Heterogeneity of Alzheimer’s Disease
Next Article in Special Issue
The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis
Previous Article in Journal
Clinician Assessment Tools for Patients with Diabetic Foot Disease: A Systematic Review
Open AccessArticle

Combined Use of Febuxostat and Colchicine Does Not Increase Acute Hepatotoxicity in Patients with Gout: A Retrospective Study

Division of Rheumatology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon 24289, Korea
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(5), 1488; https://doi.org/10.3390/jcm9051488
Received: 5 April 2020 / Revised: 12 May 2020 / Accepted: 12 May 2020 / Published: 15 May 2020
(This article belongs to the Special Issue Systemic Autoinflammatory Diseases—Clinical Rheumatic Challenges)
Colchicine has been effectively used to prevent acute flares in patients with gout, but drug-related adverse events have frequently occurred. We investigated whether colchicine therapy with febuxostat is associated with hepatotoxicity in gout patients. Gout patients treated with (n = 121) or without (n = 57) colchicine were enrolled upon initiating febuxostat as a urate-lowering treatment, and clinical and laboratory data at diagnosis were compared. Logistic regression analysis was performed to evaluate the risk factors related to hepatotoxicity. Median age of the with-colchicine and without-colchicine groups was 51.0 (37.0–62.0) and 56.0 (43.5–68.5) years, respectively. During the three months of febuxostat prescription, the prevalence of hepatotoxicity was 13/121 (10.9%) in the with-colchicine group and 4/57 (7.0%) in the without-colchicine group, without statistical significance. The rate of colchicine use was not different between the study subjects with or without hepatotoxicity (76.5% vs. 67.1%, p = 0.587). Pre-existing liver disease was significantly associated with increased risk of hepatotoxicity after febuxostat treatment (odds ratio, 4.083; 95% confidence interval, 1.326–12.577; p = 0.014). Colchicine may be safely used as a prophylactic agent for gout patients with febuxostat. However, upon initiating febuxostat, it is recommended to monitor the development of acute liver injury in gout patients with underlying liver disease. View Full-Text
Keywords: gout; febuxostat; colchicine; hepatotoxicity; prophylaxis gout; febuxostat; colchicine; hepatotoxicity; prophylaxis
Show Figures

Figure 1

MDPI and ACS Style

Oh, Y.-J.; Moon, K.W. Combined Use of Febuxostat and Colchicine Does Not Increase Acute Hepatotoxicity in Patients with Gout: A Retrospective Study. J. Clin. Med. 2020, 9, 1488. https://doi.org/10.3390/jcm9051488

AMA Style

Oh Y-J, Moon KW. Combined Use of Febuxostat and Colchicine Does Not Increase Acute Hepatotoxicity in Patients with Gout: A Retrospective Study. Journal of Clinical Medicine. 2020; 9(5):1488. https://doi.org/10.3390/jcm9051488

Chicago/Turabian Style

Oh, Yoon-Jeong; Moon, Ki W. 2020. "Combined Use of Febuxostat and Colchicine Does Not Increase Acute Hepatotoxicity in Patients with Gout: A Retrospective Study" J. Clin. Med. 9, no. 5: 1488. https://doi.org/10.3390/jcm9051488

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop